The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

Enhertu is a HER2-directed antibody and topoisomerase ... Study participants with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer who disease had progressed on endocrine therapy ...

Median progression-free survival (PFS) was 13.2 months with ENHERTU compared to 8.1 months with chemotherapy. Results were consistent in patients with HER2 low expression and HER2 ultralow expression.

The FDA will speed up their review of Enhertu for HR-positive, HER2-low/ultralow advanced breast cancer that cannot be removed via surgery. The Food and Drug Administration (FDA) granted a ...

Study results unveiled at ASCO show combining Enhertu with Perjeta can significantly delay tumor growth versus a regimen that ...

The median duration of response (DOR) was 14.3 months in the ENHERTU arm (95% CI: 12.5-15.9) versus 8.6 months in the chemotherapy arm (95% CI: 6.9-11.5) as assessed by BICR. In the HER2 low ...

In the DESTINY-Breast09 study, Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease ...

Tumors with low- and ultra-low levels of a protein called HER2 are treatable with Enhertu, but harder to identify. New ...

In the ENHERTU arm, the majority of ILD or pneumonitis events were low grade (grade 1 [n=7 ... which represent the first time a HER2 directed medicine has demonstrated a survival benefit in ...

“In DESTINY-Breast06, ENHERTU outperformed chemotherapy, providing progression-free survival of more than one year for patients with HR positive, HER2 low or HER2 ultralow metastatic breast ...